Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions

• Published in: Clinical pharmacokinetics Vol. 61; no. 2; pp. 167 - 187
• Main Authors: Hermann, Robert, Krajcsi, Peter, Fluck, Markus, Seithel-Keuth, Annick, Bytyqi, Afrim, Galazka, Andrew, Munafo, Alain
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.02.2022; Springer Nature B.V
• Subjects: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bioavailability; Breast cancer; Cancer therapies; Cladribine - pharmacology; Drug dosages; Drug Interactions; Equilibrative Nucleoside Transporter 1 - metabolism; Food; Humans; Immune system; Internal Medicine; Lifestyles; Lymphocytes; Medicine; Medicine & Public Health; Membrane Transport Proteins - metabolism; Multiple sclerosis; Neoplasm Proteins - metabolism; Nucleoside Transport Proteins; Pharmacology/Toxicology; Pharmacotherapy; Prescription drugs; Proteins; Review; Review Article
• ISSN: 0312-5963; 1179-1926; 1179-1926
• DOI: 10.1007/s40262-021-01089-9

Cladribine is a nucleoside analog that is phosphorylated in its target cells (B and T-lymphocytes) to its active triphosphate form (2-chlorodeoxyadenosine triphosphate). Cladribine tablets 10 mg (Mavenclad ® ), administered for up to 10 days per year in 2 consecutive years (3.5-mg/kg cumulative dose over 2 years), are used to treat patients with relapsing multiple sclerosis. Cladribine has been shown to be a substrate of various nucleoside transporters (NTs). Intestinal absorption and distribution of cladribine throughout the body appear to be essentially mediated by equilibrative NTs (ENTs) and concentrative NTs (CNTs), specifically by ENT1, ENT2, ENT4, CNT2 (low affinity), and CNT3. Other efficient transporters of cladribine are the ABC efflux transporters, specifically breast cancer resistance protein, which likely modulates the oral absorption and renal excretion of cladribine. A key transporter for the intracellular uptake of cladribine into B and T-lymphocytes is ENT1 with ancillary contributions of ENT2 and CNT2. Transporter-based drug interactions affecting absorption and target cellular uptake of a prodrug such as cladribine are likely to reduce systemic bioavailability and target cell exposure, thereby possibly hampering clinical efficacy. In order to manage optimized therapy, i.e., to ensure uncompromised target cell uptake to preserve the full therapeutic potential of cladribine, it is important that clinicians are aware of the existence of NT-inhibiting medicinal products, various lifestyle drugs, and food components. This article reviews the existing knowledge on inhibitors of NT, which may alter cladribine absorption, distribution, and uptake into target cells, thereby summarizing the existing knowledge on optimized methods of administration and concomitant drugs that should be avoided during cladribine treatment.